Our suggestions for the best results
By Dr. Edouard Broussalian, CEO WorldPRP, August 2020
PRP volume: except in cases where volume is critical like in Ophthalmology, we suggest to collect the full volume of obtained plasma and to blend it with the buffy coat. The important parameter in PRP is the number of injected PLT, and certainly not their concentration. Unfortunately, this latter parameter has been widely used as a sales argument, each company trying to push its own product as a reference. We prefer to develop the following important notion:
Useful dose: The useful dose concept will first define the PRP, as the clinical effect depends directly on the number of platelets released. To measure the useful dose, it will be necessary to speak of platelet yield, then qualify it using the RSI index that we have created, which is the ratio Recovery Rate%/PRPVolume%. The WorldPRP tube achieves a platelet recovery rate of 80% for 25 ml of blood sample, 87% with two samples taken from the same patient. The useful dose of platelets released ranges from 3 to 9 billion, far exceeding what is currently available on the market. https://www.worldprp.com/prp-formula
Purity: In addition to these quantitative aspects, the purity of the product obtained should be taken into account. What matters most is that the PRP should not be contaminated with red blood cells. The second point is whether or not to incorporate leukocytes in the preparation.
Our kit can be used to realize a PRP without blood cells (97.63% purity on average), with (L-PRP) or without leukocytes (LP-PRP), in a variable volume, and a concentration on request from 3x to 32x (and as it is possible to combine in a single product several autologous samples, the concentration is actually unlimited).
Anticoagulant: our clinical experience suggests that the anticoagulant promotes the fading out of PRP in the tissue as a very fluid preparation so that the PLT don’t have the time to release the growth factors where there are needed.
Instead, the experienced practitioner will be able most of time to treat the patient within 8 minutes after centrifuge so that the injected product will be activated in the tissue and transformed into PRF, diffusing there during a long time the growth factors.
This is especially clear in Orthopedics where the injected plain PRP (as opposed to fluid PRP) acts at once as a "spring" or "mattress" inside the joint; this mechanical effect will be gradually replaced by the cellular stimulation, producing a long-lasting relief.
|INDICATIONS||Volume||Plasmatic Fractions||Concentration||RSI||Useful dose (billions)|
|Face, and skin texture||3 ml||Fraction 3||8x||5||3|
|Texture and Filling||6-8 ml||Fraction 2 + 3||3x||2,86||4|
|Initial treatment||6-8 ml||Fraction 3 + Fraction 3 second kit||8x||5||6|
|Variant 1||3 ml||Fraction 3||8x||5||3|
|Variant 2||4 ml||Fraction 3 + BC 1 ml second kit||10x||12,15||8,75|
|Maintenance||6-8 ml||Fraction 2 +3||3x||2,86||4|
|DERMATOLOGY||6-8 ml||Fraction 2 + 3||3x||2,86||4|
|LASEK or LASIK||0,5 - 1 ml||BC||16x||16,25||3,25|
|Post treatment eye drops|
+ hyal acid or oflocet
|3 ml||Fraction 3||8x||5||3|
|Dry syndrome (drops)||3 ml||Fraction 3||8x||5||3|
|Macular degeneration||0,5 - 1 ml||BC||16x||16,25||3,25|
|Implants or grafts||0,5 - 1 ml||BC||16x||16,25||3,25|
|Parodontosis||2 - 3 ml||Fraction 3||8x||5||3|
|Intra cavernous injections||3 ml||Fraction 3||8x||5||3|
|G spot and around uretra||3 ml||Fraction 3||8x||5||3|
|Labia major volume improvement||4 ml||Fraction 2||6x||1,25||1|
|Intra-articular||0,5 - 1 ml||BC||16x||16,25||3,25|
|Periarticular (mesotherapy)||3 ml||Fraction 3||8x||5||3|
|Plasmatic Fraction||Volume||Platelet Recovery Rate||RSI||Useful dose (billions)|
|2||Medium PRP||4 ml||20%||1,25||1|
|3||Rich PRP + Leukocytes||3 ml||60%||5||3|
|BC concentrated by screwing of inferior part||1 ml||65%||16,25||3,25|